Allergan Acquires QLT’s Aczone, Plans Fourth Quarter Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm pays $150 million for the topical acne treatment; QLT continues sale of assets.
You may also be interested in...
QLT Divests U.S. Business, Retains Wet AMD Treatment Visudyne
Following a strategic review of its assets, Canadian company divests its only other marketed product, prostate cancer drug Eligard, and lays off 115 employees.
QLT Asks FDA To Remove Blood Screening Requirement For Acne Treatment Aczone
Firm hopes results of Phase IV study convince FDA to approve a more marketable label for the topical acne treatment.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.